[{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Canopy Growth Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canopy Growth Corporation \/ Canopy Growth Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Canopy Growth Corporation"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"James Madison University","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ James Madison University","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ James Madison University"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"University of Arkansas","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CHI-554","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"Canopy Growth Corporation \/ University of Arkansas","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ University of Arkansas"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CHI-202","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CHI-560","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Canopy Growth Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"NM Clinical Research & Osteoporosis Center","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ NM Clinical Research & Osteoporosis Center","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ NM Clinical Research & Osteoporosis Center"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"||cannabinol derivatives","graph1":"Undisclosed","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Canopy Growth Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cannabis","moa":"||Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydro","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Canopy Growth Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Canopy Growth Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Canopy Growth Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 03, 2023

                          Lead Product(s) : CHI-560,CHI-563,CHI-564,CHI-565

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 11, 2023

                          Lead Product(s) : Cannabidiol,Inapplicable

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : James Madison University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 28, 2022

                          Lead Product(s) : Tetrahydrocannabinol,Caffeine,Cannabidiol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Johns Hopkins University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          April 13, 2022

                          Lead Product(s) : Cannabis,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Recipient : Johns Hopkins University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 07, 2022

                          Lead Product(s) : Cannabidiol,Inapplicable

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : NM Clinical Research & Osteoporosis Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2022

                          Lead Product(s) : Tetrahydrocannabivarin,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 30, 2021

                          Lead Product(s) : CHI-202,Inapplicable

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 08, 2020

                          Lead Product(s) : CHI-554,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : University of Arkansas

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : CHI-902,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : Centre for Addiction and Mental Health | McMaster University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 11, 2019

                          Lead Product(s) : CHI-902,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Centre for Addiction and Mental Health | McMaster University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : CHI-921,Inapplicable

                          Therapeutic Area : Sleep

                          Study Phase : Phase II

                          Sponsor : Galenova Inc | Algorithme Pharma Inc. | Hôpital du Sacre-Cœur de Montréal | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 13, 2019

                          Lead Product(s) : CHI-921,Inapplicable

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase II

                          Sponsor : Galenova Inc | Algorithme Pharma Inc. | Hôpital du Sacre-Cœur de Montréal | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank